Literature DB >> 2272040

In vivo antitumor activity of ilmofosine.

D B Herrmann1, W Pahlke, H G Opitz, U Bicker.   

Abstract

Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. The in vivo anti-tumour activity of this compound was investigated in a methylcholanthrene (MethA)-induced fibrosarcoma and in the 3Lewis-lung carcinoma systems, respectively. Ilmofosine showed antineoplastic and antimetastatic properties at oral doses ranging from 0.625 to 40 mg/kg/day. Combination of Ilmofosine (p.o.) together with either cyclophosphamide (p.o.) or cis-DDP (i.v.) resulted in synergistic effects in vivo. These results demonstrate the in vivo antitumour activity of Ilmofosine in two tumour systems. The data indicate that direct cytostatic/cytotoxic effects of Ilmofosine are mainly responsible for its antitumour activity in vivo and which are increased by other cytotoxics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2272040     DOI: 10.1016/0305-7372(90)90055-k

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  2 in total

1.  Phase I trial of ilmofosine as a 24 hour infusion weekly.

Authors:  M von Mehren; B J Giantonio; C McAleer; R Schilder; J McPhillips; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

2.  A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.

Authors:  P V Woolley; C J Schultz; G I Rodriguez; R A Gams; K W Rowe; M L Dadey; D D Von Hoff; J J McPhillips
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.